Cost Effectiveness of Chemotherapeutic Agents and Targeted Biologics in Ovarian Cancer: A Systematic Review-Reference-Cited by-同舟云学术

Cost Effectiveness of Chemotherapeutic Agents and Targeted Biologics in Ovarian Cancer: A Systematic Review

Published:2015-06-14 Issue:11 Volume:33 Page:1155-1185
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Poonawalla Insiya B.,Parikh Rohan C.,Du Xianglin L.,VonVille Helena M.,Lairson David R.

Funder

Agency for Healthcare Research and Quality

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s40273-015-0304-9.pdf

Reference61 articles.

1. American Cancer Society. Cancer Facts & Figures 2014. Atlanta: American Cancer Society; 2014 [Internet]. Available from: http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2014/ .

2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–403.

3. American Cancer Society. Ovarian Cancer. Detailed Guide. [Internet]. Available from: http://www.cancer.org/cancer/ovariancancer/detailedguide/index .

4. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics (2014). CA Cancer J Clin. 2014;64(1):9–29.

5. Morgan RJ, Armstrong DK, Alvarez RD, Chen L, Copeland L, Crispens MA, et al. NCCN Clinical Practice Guidelines in Ovarian Cancer. v.3.2014.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness analysis of olaparib maintenance therapy for BRCA mutation ovarian cancer in the public sector in Malaysia;PLOS ONE;2024-02-01

2. Association of ideal cardiovascular health metrics with incident low estimated glomerular filtration rate: More than a decade follow-up in the Tehran Lipid and Glucose Study (TLGS);PLOS ONE;2024-02-01

3. Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer;PharmacoEconomics - Open;2022-08-29

4. Research on the Economics of Cancer-Related Health Care: An Overview of the Review Literature;JNCI Monographs;2022-07-01

5. Nano-carriers as a Selective Treatment for Cancer;Al Mustansiriyah Journal of Pharmaceutical Sciences;2022-04-19